(VIANEWS) – Shares of BENEVOLENTAI (AEX-Index: BAI.AS) slid by a staggering 31.64% in 21 sessions from €1.77 to €1.21 at 02:09 EST on Monday, after five successive sessions in a row of losses. AEX-Index is rising 0.02% to €753.52, following the last session’s upward trend.
BENEVOLENTAI’s last close was €1.21, 83.87% below its 52-week high of €7.50.
About BENEVOLENTAI
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.7.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -152.53%.
Yearly Top and Bottom Value
BENEVOLENTAI’s stock is valued at €1.21 at 02:09 EST, under its 52-week low of €1.34.
More news about BENEVOLENTAI (BAI.AS).
